Ségolène Hescot1, Atmane Seck1, Maryse Guerin1, Florence Cockenpot1, Thierry Huby1, Sophie Broutin1, Jacques Young1, Angelo Paci1, Eric Baudin1, Marc Lombès1. 1. Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche (INSERM UMR)-S 1185 (S.H., J.Y., E.B., M.L.), Le Kremlin-Bicêtre F-94276, France; Department of Nuclear Medicine and Endocrine Oncology (S.H., E.B.) and Department of Pharmacology (A.S., F.C., S.B., A.P., E.B.), Gustave Roussy, Villejuif F-94805, France; INSERM UMR-S Institute of Cardiometabolism and Nutrition/1166, (M.G., T.H.) Pitié-Salpetrière Hospital, Paris, F-75013, France; Department of Endocrinology (J.Y., M.L.), Centre Hospitalier Universitaire Bicêtre, Le Kremlin-Bicêtre F-94276, France.
Abstract
CONTEXT: Mitotane (o,p'-DDD), the only approved drug for advanced adrenocortical carcinoma (ACC), is a lipophilic agent that accumulates into circulating lipoprotein fractions and high-lipid-containing tissues. OBJECTIVE: The aim of our study was to evaluate the in vivo and in vitro biological implication of serum lipoproteins on pharmacological action of mitotane. Distribution and concentration of mitotane were studied in plasma and adrenal tissue samples from mitotane-treated patients. The effect of lipoprotein-bound or lipoprotein-free (LP-F) mitotane was analyzed on proliferation and apoptosis of human adrenocortical H295R cells. A retrospective study of patients with ACC treated or not with statins was also performed. RESULTS: o,p'-DDD distribution among very low-density lipoprotein, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and LP-F fractions obtained after plasma ultracentrifugation of 23 of mitotane-treated patients was widely distributed in each subfraction. A positive correlation was observed between mitotane levels in plasma and in LDL, HDL, but also LP-F compartment. Intratumor o,p'-DDD concentrations in five ACC samples of mitotane-treated patients were found to be independent of cholesterol transporter expression, scavenger receptors, and LDL receptors. In vitro studies showed significant higher antiproliferative and proapoptotic effects and higher cell and mitochondrial uptake of mitotane when H295R cells were grown in LP-F medium. Finally, retrospective study of an ACC cohort of 26 mitotane-treated patients revealed that statin therapy was significantly associated with a higher rate of tumor control. CONCLUSIONS: Altogether, our in vitro and in vivo studies provided compelling evidence for a greater efficacy of LP-F mitotane. Patients with ACC may thus benefit from therapeutic strategies that aim to increase LP-F mitotane fraction.
CONTEXT: Mitotane (o,p'-DDD), the only approved drug for advanced adrenocortical carcinoma (ACC), is a lipophilic agent that accumulates into circulating lipoprotein fractions and high-lipid-containing tissues. OBJECTIVE: The aim of our study was to evaluate the in vivo and in vitro biological implication of serum lipoproteins on pharmacological action of mitotane. Distribution and concentration of mitotane were studied in plasma and adrenal tissue samples from mitotane-treated patients. The effect of lipoprotein-bound or lipoprotein-free (LP-F) mitotane was analyzed on proliferation and apoptosis of humanadrenocortical H295R cells. A retrospective study of patients with ACC treated or not with statins was also performed. RESULTS:o,p'-DDD distribution among very low-density lipoprotein, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and LP-F fractions obtained after plasma ultracentrifugation of 23 of mitotane-treated patients was widely distributed in each subfraction. A positive correlation was observed between mitotane levels in plasma and in LDL, HDL, but also LP-F compartment. Intratumor o,p'-DDD concentrations in five ACC samples of mitotane-treated patients were found to be independent of cholesterol transporter expression, scavenger receptors, and LDL receptors. In vitro studies showed significant higher antiproliferative and proapoptotic effects and higher cell and mitochondrial uptake of mitotane when H295R cells were grown in LP-F medium. Finally, retrospective study of an ACC cohort of 26 mitotane-treated patients revealed that statin therapy was significantly associated with a higher rate of tumor control. CONCLUSIONS: Altogether, our in vitro and in vivo studies provided compelling evidence for a greater efficacy of LP-F mitotane. Patients with ACC may thus benefit from therapeutic strategies that aim to increase LP-F mitotane fraction.
Authors: Ewelina Stelcer; Hanna Komarowska; Karol Jopek; Agnieszka Żok; Dariusz Iżycki; Agnieszka Malińska; Beata Szczepaniak; Zhanat Komekbai; Marek Karczewski; Tomasz Wierzbicki; Wiktoria Maria Suchorska; Marek Ruchała; Marcin Ruciński Journal: Oncol Lett Date: 2022-02-10 Impact factor: 2.967
Authors: Kate M Warde; Yi Jan Lim; Eduardo Ribes Martinez; Felix Beuschlein; Paula O'Shea; Constanze Hantel; Michael Conall Dennedy Journal: Endocrinology Date: 2022-09-01 Impact factor: 5.051
Authors: Sarah Allegra; Soraya Puglisi; Chiara Borin; Francesco Chiara; Vittoria Basile; Anna Calabrese; Giuseppe Reimondo; Silvia De Francia Journal: Biomedicines Date: 2022-08-03
Authors: Angelo Paci; Ségolène Hescot; Atmane Seck; Christel Jublanc; Lionel Mercier; Delphine Vezzosi; Delphine Drui; Marcus Quinkler; Martin Fassnacht; Eric Bruckert; Marc Lombès; Sophie Leboulleux; Sophie Broutin; Eric Baudin Journal: Endocrinol Diabetes Metab Case Rep Date: 2016-06-10
Authors: Malik Salman Haider; Taufiq Ahmad; Jürgen Groll; Oliver Scherf-Clavel; Matthias Kroiss; Robert Luxenhofer Journal: Eur J Drug Metab Pharmacokinet Date: 2021-07-21 Impact factor: 2.441